PIPELINES
Immunotherapies for cancer, designed by Arpelos
PIPELINEs
Our three IO programs each target a key cancer resistance mechanism that inhibits an effective antitumor response. With the novel checkpoint LAG-3, we are advancing ALP-501. For CD73, an enzyme generating immunosuppressive adenosine, we are advancing ALP-742. For CSF1R, a receptor driving macrophage-mediated suppression, we are advancing ALP-319.
Our Pipeline
Modern drug discovery is limited by models that oversimplify biology. Arpelos was founded to change that. Our platform uses fresh human blood and high-dimensional single-cell profiling to capture how compounds behave across real, diverse cell populations—before a molecule ever enters the clinic.
This funding enables us to advance our core platform: boosting throughput, broadening functional readouts, and enhancing the resolution of our cellular insights. With richer data, improved models, and smarter tools, we aim to deliver unprecedented clarity into drug behavior within human biology.
Neurolmmuno Therapeutics
Modern drug discovery is limited by models that oversimplify biology. NeuroImmuno Therapeutics was founded to change that. Our platform uses fresh human blood and high-dimensional single-cell profiling to capture how compounds behave across real, diverse cell populations—before a molecule ever enters the clinic.
About Us
We are a biotechnology company pioneering precision medicines for neuroimmune disorders. At Arpelos, we integrate deep immunology with advanced neuroscience to develop targeted therapies. Our team brings together cutting-edge science, data-driven discovery, and a commitment to transforming the lives of patients with serious neurological conditions.
LEARN MORE
Our Science
Our science begins where conventional models fall short. At Arpelos, we study drug behavior in fresh human blood using high-dimensional single-cell profiling. This allows us to see how compounds act across real immune cell types—capturing complexity, predicting responses, and informing better decisions earlier in the discovery process.
LEARN MORE
